Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

BusinesswireDec 10 07:30 ET

Facet Life Sciences Named Regulatory Partner for Cybin's Neuropsychiatry Therapeutics Development Pipeline

PR NewswireDec 4 14:00 ET

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

BusinesswireDec 4 07:30 ET

Cybin Inc. Advances in Mental Health Treatments

TipRanksNov 25 22:58 ET

Express News | Cybin Inc - Cyb003 Demonstrates Excellent Safety Profile

ReutersNov 18 07:01 ET

Express News | Cybin Inc - 100% Response, 71% Remission at 12 Months With Cyb003

ReutersNov 18 07:01 ET